Earnings call transcript: Oxford Biomedica H1 2026 misses forecasts, shares rise

Oxford Biomedica reported H1 2026 revenue of GBP 80.2 million, up 10% year over year at constant currency, but missed analyst expectations with EPS of -$0.3039 versus -$0.245 forecast and revenue of $79.85 million versus $98.10 million, an 18.6% shortfall. Adjusted EBITDA loss improved to GBP 2.5 million from GBP 3.9 million, although a GBP 7.6 million France-site impairment and delays in client programs and Durham's ramp weighed on results. Management maintained FY2026 revenue guidance of GBP 180 million-GBP 200 million, supported by GBP 168 million of contracted revenue coverage; shares rose 2.04% as investors focused on backlog growth, unchanged guidance and the now-operational Durham facility.

Analysis

OXB’s unchanged full-year range masks a demanding second-half conversion requirement: revenue must accelerate materially from H1 while customers increasingly authorize work in smaller tranches. Contract coverage reduces cancellation risk only for signed scope; it does not eliminate batch timing, release, or client-funding risk. The France impairment is the more important signal than the headline backlog: it indicates that capacity utilization, rather than nominal network breadth, will determine whether fixed-cost leverage materializes.

The near-term equity setup is asymmetric to the downside after a benign reaction to a sizeable miss. A second delay at Durham, lower H2 batch throughput, or a reduction in the guide would challenge both the 2027 double-digit EBITDA target and the long-dated 30% margin narrative; with limited net cash after working-capital outflows and planned capex, the valuation is likely more sensitive to cash conversion than EBITDA adjustments. Over 6-18 months, a successful ramp in U.S. AAV manufacturing could differentiate OXB from smaller vector CDMOs, but the same spare capacity that supports upside also leaves it exposed to price competition if biotech financing weakens.

CABA and KYTX are potentially valuable demand-validation indicators rather than clean OXB read-through longs: their clinical progress can pull forward manufacturing volume, but each sponsor remains exposed to financing, regulatory timing, and patient-enrollment volatility. The market may be underestimating that staged European contracting structurally extends revenue-recognition cycles even when end demand is intact. BABA is unrelated article contamination and offers no actionable linkage to this thesis.

Key Decisions for Investors

• Maintain an underweight/short bias in OXB into the next trading update; use a post-results rally to initiate only if liquidity permits. Target 15-25% downside on an H2 execution or cash-conversion disappointment; cover if management demonstrates Durham batch delivery and reiterates guidance with contracted coverage above the low end plus credible working-capital release.
• Do not underwrite the 2027 margin target until site-level utilization, gross margin, and cash burn are disclosed. Set an alert for any reduction in the GBP 180m-GBP 200m revenue range, further France restructuring, or net-cash deterioration after capex; any of these would raise financing-risk odds within 6-12 months.
• For a higher-risk positive catalyst basket, monitor CABA and KYTX around clinical/regulatory updates rather than buy OXB solely for their exposure. A favorable late-stage data or filing milestone could improve OXB’s commercial-volume visibility over 12-24 months; clinical setbacks or financing delays would falsify that demand pull-through.
• Avoid treating contracted backlog as equivalent to near-term revenue. Reassess a long OXB only after evidence that H2 revenue run-rate reaches roughly GBP 100m or better and adjusted EBITDA turns sustainably positive without one-off benefits; this is the minimum operational proof point for multiple expansion.